Masquelet Induced-Membrane Technique for Segmental Bone Loss

TraumaAdvancedCore Procedure

Masquelet Induced-Membrane Technique for Segmental Bone Loss

Two-stage induced-membrane technique for critical-size segmental bone defects from trauma, infection or tumour resection — radical debridement, PMMA spacer induction, membrane preservation and autograft reconstruction

High-yield overview

Two-stage reconstruction of critical-size segmental bone defects using an induced vascularised biomembrane | advanced

Surgical Imaging

Critical Danger Structures and Exam Traps
Radical Debridement Endpoint

The trap: Stopping debridement when bone looks 'clean' rather than when healthy bleeding bone is reached — residual necrotic bone leads to persistent infection and graft failure.

The fix: Debride until punctate bleeding is seen from all bone surfaces (the 'paprika sign'); use high-speed burr or curettes under irrigation to reach viable bone. In infected cases send multiple deep tissue and bone samples for culture before inserting the spacer.

Membrane Preservation at Stage Two

The trap: Incising or tearing the induced membrane during spacer removal or graft packing — once torn the membrane loses its containment and inductive properties.

The fix: Make a single longitudinal incision through the membrane only; use blunt dissection and periosteal elevators to elevate it gently as a continuous sheet from the surrounding soft tissues. Protect it with moist packs throughout the procedure.

Fixation Stability Across Stages

The trap: Converting from external fixation in stage one to definitive internal fixation too early in stage two without confirming infection clearance — hardware becomes a nidus for recurrent infection.

The fix: In infected defects keep external fixation until stage two and only then consider conversion to plate or nail once cultures from stage two are negative. For aseptic defects, internal fixation can be used from stage one provided soft-tissue coverage is adequate.

Infection Eradication Before Grafting

The trap: Proceeding to stage two while low-grade infection persists — the graft will be resorbed or become infected.

The fix: Stage two is only performed when clinical signs of infection have resolved, inflammatory markers (CRP, ESR) have normalised, and there is no ongoing drainage. If doubt exists, repeat debridement and spacer exchange rather than grafting into an infected bed.

Donor-Site Morbidity with Large Defects

The trap: Underestimating autograft volume required — defects greater than 5 cm often need more than 50-100 mL of cancellous graft, leading to excessive iliac crest harvest morbidity.

The fix: Plan graft volume pre-operatively using CT; use posterior iliac crest (higher volume, less pain than anterior), consider RIA (reamer-irrigator-aspirator) from the femur for large-volume harvest, and use allograft/BMA extenders liberally.

Timing of Definitive Fixation

The trap: Leaving the external fixator in place for the entire consolidation period (greater than 6 months) — pin-site infection, joint stiffness and patient intolerance increase dramatically.

The fix: Convert to internal fixation (plate or intramedullary nail) at stage two once the membrane is closed and graft is in place, provided soft tissues are healthy. External fixation is maintained only until stage two in most trauma cases.

Mnemonic

M.A.S.Q.U.E.L.E.TMASQUELET — Two-Stage Principles

Mnemonic

D.E.F.E.C.TDEFECT — Decision Framework for Segmental Bone Loss

Indications for the Masquelet Technique

Primary Indications

  • Post-traumatic segmental bone loss greater than 2 cm after high-energy open fractures (Gustilo IIIB/C)
  • Infected nonunion with bone defect after radical debridement (most common indication)
  • Aseptic nonunion with segmental defect after failed prior fixation
  • Bone defects after tumour resection (primary bone tumours or metastases) when limb salvage is planned
  • Congenital pseudarthrosis of the tibia or other dysplastic segmental defects (selected cases)

Contraindications

Absolute:

  • Active uncontrolled infection with systemic sepsis
  • Inadequate soft-tissue envelope that cannot be reconstructed
  • Severe peripheral vascular disease precluding graft vascularisation
  • Patient unable or unwilling to comply with staged surgery and prolonged rehabilitation

Relative:

  • Defects less than 2 cm (direct autografting or acute shortening preferable)
  • Defects greater than 8-10 cm in the tibia (bone transport or free vascularised fibula may be superior)
  • Heavy smokers or poorly controlled diabetics (optimise first or consider alternative)

Evidence Base and Outcomes

The original description by Masquelet in 2000 reported union in 35 of 35 patients with defects averaging 4.7 cm using the two-stage technique. Subsequent series have confirmed union rates of 80-95% for defects 2-6 cm when radical debridement and stable fixation are achieved.

Key advantages over alternative techniques:

  • Simpler than vascularised fibula transfer (no microsurgery required)
  • Shorter treatment time than Ilizarov bone transport for moderate defects
  • The membrane provides both mechanical containment and biological induction, improving graft survival compared with grafting into scarred tissue

Limitations:

  • Requires two major operations
  • Autograft donor-site morbidity for large defects
  • Not ideal for very long defects (greater than 8 cm) where transport or vascularised graft may be better

Clinical Decision Scenarios

Practise clinical reasoning and management decisions out loud

Viva scenarioAdvanced
Clinical prompt

A 42-year-old man sustains an open Gustilo IIIB fracture of the tibial shaft with 5 cm segmental bone loss after a motorbike accident. He undergoes initial debridement and external fixation. At 6 weeks there is no infection but a persistent 5 cm defect. How would you reconstruct this?

Practical approach
This is a classic indication for the two-stage Masquelet induced-membrane technique. The defect size (5 cm) is ideal for Masquelet — large enough that direct grafting would fail due to resorption, yet small enough that bone transport would be unnecessarily prolonged. **Stage one plan**: I would perform radical debridement to healthy bleeding bone at both ends, confirm with the paprika sign, obtain multiple cultures, and insert an antibiotic-loaded PMMA spacer filling the defect. The existing external fixator would be maintained or revised for optimal stability and alignment. Soft-tissue coverage would be coordinated with plastic surgery (likely a free flap) at this stage. **Timing of stage two**: I would wait 6-8 weeks, monitoring for normalisation of CRP and ESR, resolution of any wound issues, and maturation of the induced membrane. Stage two would only proceed once there are no clinical or biochemical signs of infection. **Stage two technique**: Re-open the wound, incise the membrane longitudinally, carefully elevate it as an intact sheet, remove the spacer, harvest posterior iliac crest autograft (approximately 60-80 mL), pack the membrane cavity densely, and close the membrane over the graft. At the same procedure I would convert the external fixator to a locked medial plate or intramedullary nail for definitive stabilisation. **Rehabilitation**: Protected weight-bearing progressing to full by 4-6 months, with union expected at 8-10 months. I would counsel the patient pre-operatively about the two-stage nature, donor-site morbidity, and the 6-12 month timeline to union.
Viva scenarioAdvanced
Clinical prompt

Six months after stage-two Masquelet grafting for a 6 cm tibial defect, radiographs show incomplete consolidation at the proximal host-graft junction with 3 mm lucency and no bridging callus. The patient has mild discomfort but no signs of infection. What is your management?

Practical approach
This scenario represents delayed union at the proximal junction, a recognised complication occurring in 10-20% of larger defects. I would first confirm there is no occult infection with inflammatory markers and, if elevated, aspiration or biopsy. Assuming infection has been excluded, my approach would be: **Initial management (6-9 months)**: Continue protected weight-bearing, optimise biology (vitamin D, smoking status, nutrition), and obtain a CT to assess the volume of bridging callus and the mechanical environment. If the fixation is stable, a further 3 months of observation with functional bracing is reasonable. **Surgical options if no progress by 9-12 months**: Revision with exchange nailing (if nail was used) or addition of a posterolateral bone graft outside the membrane to stimulate the junction. In some cases I would re-open the membrane, refresh the bone ends, and add more autograft with BMP-2 or concentrated bone marrow aspirate. **Prevention in future cases**: Ensure the graft is packed in direct contact with bleeding cancellous bone inside the medullary canal at both ends; use a longer plate spanning well beyond the defect; consider primary use of RIA graft plus allograft extenders for defects approaching 6 cm.
Viva scenarioAdvanced
Clinical prompt

A 35-year-old woman with an infected nonunion of the femur after failed exchange nailing has a 7 cm segmental defect. She is a heavy smoker. Compare the Masquelet technique with Ilizarov bone transport and vascularised fibula transfer for this patient.

Practical approach
This is a borderline defect size (7 cm) where all three techniques are reasonable, but patient factors (smoking, female, infected nonunion) influence the choice. **Masquelet advantages in this case**: Two operations rather than prolonged external fixation; the membrane provides containment and induction even in a scarred bed; conversion to internal fixation at stage two reduces pin complications. Success rate remains 80-85% even in smokers if infection is controlled. **Ilizarov bone transport advantages**: Single definitive procedure (though lengthy); no donor-site morbidity; excellent for very long defects; the regenerate is living bone. Disadvantages: 1 mm/day transport means 70+ days of transport plus docking time, high pin-site infection risk, and knee/ankle stiffness from prolonged frame time. Smoking markedly increases regenerate complications. **Vascularised fibula transfer advantages**: Living bone with its own blood supply, good for irradiated or severely scarred beds. Disadvantages: microsurgical expertise required, donor-site morbidity (ankle instability, weakness), longer operative time, and higher early failure rate if vascular anastomosis fails. **My recommendation for this patient**: Masquelet is the most pragmatic choice. She can undergo radical debridement and spacer placement now, optimise smoking cessation during the membrane induction period, and have internal fixation at stage two. Bone transport would be my second choice if she refuses two operations or has a very long defect. Vascularised fibula would be reserved for cases where soft-tissue quality is extremely poor or previous Masquelet has failed.
Exam day cheat sheet
Masquelet Induced-Membrane Technique — Exam Day Summary

References

Evidence

Reconstruction of long bone defects after trauma or infection using the induced membrane technique

Level IV
Masquelet AC, Fitoussi F, Begue T, Muller GPAnn Chir Plast Esthet
Evidence

Treatment of posttraumatic bone defects by the induced membrane technique

Level IV
Karger C, Kishi T, Schneider L, Fitoussi F, Masquelet ACOrthop Traumatol Surg Res
Evidence

Two-stage reconstruction of post-traumatic segmental tibia bone loss with nailing

Level IV
Apard T, Bigorre N, Cronier P, Duteille F, Bizot P, Massin POrthop Traumatol Surg Res
Evidence

Management of septic non-union of the tibia by the induced membrane technique. What factors could improve results?

Level IV
Siboni R, Joseph E, Blasco L, Barbe C, Bajolet O, Diallo S, Ohl XOrthop Traumatol Surg Res

Editorially reviewed — transparent references and correction processPublished by OrthoVellum Medical Education TeamEditorial boardMethodologyReview policy
Educational disclosure

Educational content is reviewed for source visibility, editorial coherence, and correction readiness.

No individual clinician credential is claimed unless a named person is shown.

Verify before clinical use; this is not medical advice or a substitute for local guidance.